Marketdash
Back to Stock Market News

Axsome Therapeutics Scores FDA Priority Review for Alzheimer's Drug

MarketDash Editorial Team
4 hours ago
Axsome Therapeutics received FDA Priority Review for its Alzheimer's agitation treatment and cleared a key regulatory hurdle for its narcolepsy drug, sending shares soaring to new 52-week highs.

Axsome Therapeutics Inc. (AXSM) had a very good Wednesday. The FDA accepted the company's supplemental New Drug Application for AXS-05, a combination of dextromethorphan HBr and bupropion HCl designed to treat agitation in Alzheimer's disease patients. Better yet, the agency granted Priority Review status and set a decision deadline of April 30, 2026.

For context, Priority Review is the FDA's way of saying "we'll move faster on this one because it matters." Instead of the usual 10-month review timeline, the agency aims to make a decision within 6 months. It's typically reserved for treatments that could offer significant improvements over existing options or address unmet medical needs.

The supplemental NDA builds on an extensive clinical development program that included four randomized, double-blind, controlled Phase 3 trials plus a long-term safety study. That's a lot of data backing up the application, which probably helped secure the Priority Review designation.

Narcolepsy Drug Clears Key Regulatory Hurdle

The good news didn't stop there. Axsome also announced it received formal pre-NDA meeting minutes from the FDA regarding AXS-12 for narcolepsy. Narcolepsy is a chronic neurological disorder that causes uncontrollable daytime sleepiness, sudden sleep attacks, and disrupted nighttime sleep—basically your sleep-wake cycle goes haywire.

These pre-NDA meetings are crucial because they're where companies and the FDA hash out what needs to be in the actual drug application. According to the meeting minutes, Axsome's regulatory data package would be sufficient for submitting an NDA for AXS-12 to treat cataplexy in narcolepsy. Cataplexy is that particularly alarming symptom where people suddenly lose muscle control, sometimes triggered by strong emotions.

The company plans to complete the NDA submission in January 2026. The clinical program supporting this application includes three controlled efficacy trials and a completed long-term safety trial. Of course, the FDA will still need to review the complete filing before formally accepting it, but this feedback is about as close to a green light as you get before actually submitting.

Wall Street Reaction

Needham analysts clearly liked what they saw, maintaining their Buy rating on Axsome Therapeutics while bumping their price target from $154 to $169. Investors were even more enthusiastic—shares jumped 18.18% to $175.84, hitting a fresh 52-week high. Not a bad day at the office for Axsome shareholders.

Back to Stock Market News

Axsome Therapeutics Scores FDA Priority Review for Alzheimer's Drug

MarketDash Editorial Team
4 hours ago
Axsome Therapeutics received FDA Priority Review for its Alzheimer's agitation treatment and cleared a key regulatory hurdle for its narcolepsy drug, sending shares soaring to new 52-week highs.

Axsome Therapeutics Inc. (AXSM) had a very good Wednesday. The FDA accepted the company's supplemental New Drug Application for AXS-05, a combination of dextromethorphan HBr and bupropion HCl designed to treat agitation in Alzheimer's disease patients. Better yet, the agency granted Priority Review status and set a decision deadline of April 30, 2026.

For context, Priority Review is the FDA's way of saying "we'll move faster on this one because it matters." Instead of the usual 10-month review timeline, the agency aims to make a decision within 6 months. It's typically reserved for treatments that could offer significant improvements over existing options or address unmet medical needs.

The supplemental NDA builds on an extensive clinical development program that included four randomized, double-blind, controlled Phase 3 trials plus a long-term safety study. That's a lot of data backing up the application, which probably helped secure the Priority Review designation.

Narcolepsy Drug Clears Key Regulatory Hurdle

The good news didn't stop there. Axsome also announced it received formal pre-NDA meeting minutes from the FDA regarding AXS-12 for narcolepsy. Narcolepsy is a chronic neurological disorder that causes uncontrollable daytime sleepiness, sudden sleep attacks, and disrupted nighttime sleep—basically your sleep-wake cycle goes haywire.

These pre-NDA meetings are crucial because they're where companies and the FDA hash out what needs to be in the actual drug application. According to the meeting minutes, Axsome's regulatory data package would be sufficient for submitting an NDA for AXS-12 to treat cataplexy in narcolepsy. Cataplexy is that particularly alarming symptom where people suddenly lose muscle control, sometimes triggered by strong emotions.

The company plans to complete the NDA submission in January 2026. The clinical program supporting this application includes three controlled efficacy trials and a completed long-term safety trial. Of course, the FDA will still need to review the complete filing before formally accepting it, but this feedback is about as close to a green light as you get before actually submitting.

Wall Street Reaction

Needham analysts clearly liked what they saw, maintaining their Buy rating on Axsome Therapeutics while bumping their price target from $154 to $169. Investors were even more enthusiastic—shares jumped 18.18% to $175.84, hitting a fresh 52-week high. Not a bad day at the office for Axsome shareholders.

    Axsome Therapeutics Scores FDA Priority Review for Alzheimer's Drug - MarketDash News